Anzeige
Mehr »
Freitag, 31.10.2025 - Börsentäglich über 12.000 News
Attestation ist die Killer-App - Republic baut sie jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CU1G | ISIN: US29479A1088 | Ticker-Symbol:
NASDAQ
31.10.25 | 20:59
2,435 US-Dollar
-1,02 % -0,025
1-Jahres-Chart
ERASCA INC Chart 1 Jahr
5-Tage-Chart
ERASCA INC 5-Tage-Chart

Aktuelle News zur ERASCA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.10.Stifel initiates coverage on Erasca stock with Buy rating, $4 price target1
03.09.Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts3
03.09.BofA Securities downgrades Erasca stock to Underperform on competitive concerns6
18.08.Morgan Stanley stuft Erasca-Aktie wegen verzögerter Studiendaten herab1
18.08.Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data1
12.08.Erasca files $500M mixed securities shelf2
ERASCA Aktie jetzt für 0€ handeln
12.08.Erasca, Inc. - 10-Q, Quarterly Report1
12.08.Erasca, Inc. - 8-K, Current Report1
12.08.Erasca, Inc.: Erasca Reports Second Quarter 2025 Business Updates and Financial Results224Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance...
► Artikel lesen
26.06.Erasca, Inc. - 8-K, Current Report2
02.06.Erasca Announces Clearance Of IND Application By FDA For ERAS-4001-
02.06.FDA clears Erasca's new cancer drug applications1
13.05.Erasca, Inc. - 10-Q, Quarterly Report2
13.05.Erasca, Inc.: Erasca Reports First Quarter 2025 Business Updates and Financial Results135Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026...
► Artikel lesen
13.05.Erasca, Inc. - 8-K, Current Report1
13.05.Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset1
13.05.FDA clears Erasca's new cancer drug ERAS-00151
20.03.Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results650Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well...
► Artikel lesen
12.11.24Erasca, Inc.: Erasca Reports Third Quarter 2024 Business Updates and Financial Results569Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1